• Cytek Biosciences to Report Fourth Quarter and Full Year 2021 Financial Results on February 23, 2022

    Источник: Nasdaq GlobeNewswire / 11 фев 2022 08:00:00   America/New_York

    FREMONT, Calif., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), today announced it will report financial results for the fourth quarter and full year 2021 after market close on Wednesday, February 23rd, 2022. The company’s management will webcast a corresponding conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its results, business developments and outlook.

    Live audio of the webcast will be available on the “Investors” section of the company website at investors.cytekbio.com

    About Cytek Biosciences
    Cytek Biosciences is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with exquisite sensitivity. Cytek’s FSP platform includes its core instruments, the Aurora and Northern Lights™ systems, its cell sorter, the Aurora CS, and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe.

    Other than Cytek’s Northern Lights CLC system, which is available for clinical use in China and the European Union, Cytek’s products are for research use only – not for use in diagnostic procedures or for clinical purposes.

    Cytek, Full Spectrum Profiling, FSP and Northern Lights are trademarks or registered trademarks of Cytek Biosciences, Inc.

    Investor Relations Contact:
    Carrie Mendivil/Alex Khan
    Gilmartin Group LLC
    investors@cytekbio.com 

    Media Contact:
    Stephanie Olsen
    Lages & Associates
    (949) 453-8080
    stephanie@lages.com 


    Primary Logo

Опубликовать